Trending Articles

article thumbnail

H5N1 bird flu virus particles found in pasteurized milk but FDA says commercial milk supply appears safe

STAT

WASHINGTON — Testing conducted by the Food and Drug Administration on pasteurized commercially purchased milk has found genetic evidence of the H5N1 bird flu virus, the agency confirmed Tuesday. But the testing, done by polymerase chain reaction, or PCR, cannot distinguish between live virus or fragments of viruses that could have been killed by the pasteurization process.

364
364
article thumbnail

Vistagen’s on-demand nasal spray could provide a novel option for social anxiety

PharmaVoice

The fast-acting medication is one of a few new approaches being tested for the crippling condition.

288
288
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Behind the ‘encouraging’ new results for Amylyx’s beleaguered drug

PharmaVoice

Where Amylyx ultimately failed in ALS, it could prevail in a rare disease. The doctor leading this research explains why.

299
299
article thumbnail

Top 20 global biopharma companies report 9.6 per cent market cap growth in Q1 2024: GlobalData

Express Pharma

Despite the ongoing uncertainties surrounding macroeconomic activities, fluctuating interest rates, and changes in the Medicare Drug Price Negotiation landscape, the top 20 global biopharma companies experienced a promising first quarter this year. They reported a total increase of 9.6 per cent in market capitalisation from $3.67 trillion as on 31 December 2023 to $4 trillion as on 31 March 2024, reveals GlobalData.

article thumbnail

Position Your Pharmacy for Expansion

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

article thumbnail

What pharma stands to gain from technological innovation

pharmaphorum

Pharmaceutical companies stand to gain significant benefits from technological innovation in the form of improved data analytics, streamlined healthcare processes, and enhanced patient outcomes. Explore the potential advantages for the pharma industry.

article thumbnail

Metsera, a well-funded obesity drug startup, sees chance to challenge Lilly, Novo

BioPharma Dive

It’s “early innings” in the obesity drug race, said Metsera CEO Clive Meanwell, whose company has acquired a portfolio of medicines it aims to test in combination.

124
124

More Trending

article thumbnail

Innovative Strategies in Drug Repurposing

Drug Patent Watch

Drug repurposing, or identifying new therapeutic uses for existing drugs, is gaining significant momentum as a promising approach to accelerate drug development and reduce costs.

article thumbnail

Novartis names ex-BMS CEO Caforio as chair amid strong Q1

pharmaphorum

Novartis has proposed ex-BMS CEO Caforio as the successor to chair Joerg Reinhardt when he steps down next year, as it posts a strong set of Q1 results

111
111
article thumbnail

Zydus launches Mirabegron ER tablets in US

Express Pharma

Zydus Lifesciences has launched Mirabegron Extended-Release Tablets, 25 mg in the US market. The company had earlier received final approval from the United States Food and Drug Administration (USFDA) to market Mirabegron Extended-Release Tablets USP 25 mg and 50 mg (USRLD: Myrbetriq Extended-Release Tablets). Zydus is among the first suppliers to launch the generic version of Mirabegron Extended-Release Tablets, USP 25 mg in the US market and is prepared to launch Mirabegron Extended-Release Ta

105
105
article thumbnail

STAT+: In a scientific first, researchers use CRISPR base editing to treat liver disease in fetal monkeys

STAT

The ambitious idea of using CRISPR to cure genetic diseases before birth is one step closer to reality. Scientists reported on Monday that they used a form of the technology known as “ base editing ” to alter the DNA of laboratory monkeys in the womb, substantially reducing the levels of a toxic protein that causes a fatal liver disease before the animals had even been born.

Packaging 363
article thumbnail

5 Reasons to Upgrade Your Pharmacy Management Software

Are you still using workarounds to manage your daily operations? To achieve peak performance, it's time to explore other options for specialty and infusion pharmacy software. Streamline pharmacy operations and improve clinical performance with automated processing, real-time data exchange, and electronic decision support. Download this helpful infographic to: Drive efficiency and patient adherence from referral receipt to delivery and ongoing care – all with our Pharmacy Cloud.

article thumbnail

Inside J&J’s strategy to de-gender clinical trials

PharmaVoice

Mark Wildgust, vice president of global medical affairs for J&J's oncology division, shares strategies for making clinical trials gender- and trans-inclusive.

182
182
article thumbnail

Vertex begins bid for US approval of non-opioid painkiller

BioPharma Dive

The start of a so-called rolling review formally begins an FDA evaluation of a closely watched drug that’s important to the biotech’s future, but faces questions about its sales potential.

119
119
article thumbnail

With $75m cash injection, SynOx plans ph3 rare tumour trial

pharmaphorum

Ireland’s SynOx Therapeutics has completed a second-round financing, raising $75 million, as it prepares to take its drug for tenosynovial giant cell tumour (TGCT) into phase 3 trials. TGCT is a rare disease affecting the joints and tendons caused by overproduction of the protein CSF-1, which stimulates the proliferation of various cell types, inflammation, and destruction of the matrix of the joint.

105
105
article thumbnail

New patent expiration for Galderma Labs drug SOOLANTRA

Drug Patent Watch

Annual Drug Patent Expirations for SOOLANTRA Soolantra is a drug marketed by Galderma Labs Lp and is included in one NDA. It is available from three suppliers.

105
105
article thumbnail

Hospitals largely keep quiet on maternal care since Dobbs, STAT survey finds

STAT

The Supreme Court decision to overturn Roe v. Wade has transformed not just abortion access but maternal health care across the United States, causing physicians in states with restrictive laws to shift treatment of conditions including ectopic pregnancy and miscarriage. The full scale of the impact, though, has been obscured in a polarized political climate where physicians are often afraid to speak out, or are blocked by their hospitals from talking about their experiences post-Dobbs.

Hospitals 357
article thumbnail

Outrun Therapeutics announces launch with $10m seed funding

Pharmaceutical Technology

Outrun Therapeutics announced its launch with $10m seed funding to advance a protein stabilisation pipeline focused on E3 ligase inhibitors.

126
126
article thumbnail

Cerevel, in ‘major surprise,’ finds success in late-stage Parkinson’s study

BioPharma Dive

Analysts had low expectations for Cerevel’s drug tavapadon, which was something of an afterthought in AbbVie’s proposed buyout of the biotech.

122
122
article thumbnail

EU approves Pfizer antibiotic for superbug infections

pharmaphorum

Pfizer’s Emblaveo has been approved in the EU with a first-in-class indication in multidrug-resistant (MDR) infections. The drug – a combination of beta-lactam antibiotic aztreonam with beta-lactamase inhibitor avibactam – is the first drug of this type to get a green light from the European Commission to treat serious infections caused by MDR Gram-negative bacteria in adults.

101
101
article thumbnail

Pharmacy First: Top tips for managing acute sore throats

The Pharmacist

CLINICAL UPDATE The Pharmacy First service in England enables pharmacists to diagnose and treat seven specific conditions, which should hopefully reduce some of the current pressures on general practice. This series of guides assumes that pharmacists are familiar with the clinical pathways and requirements for Pharmacy First. The articles explore some key aspects of each […] The post Pharmacy First: Top tips for managing acute sore throats appeared first on The Pharmacist.

91
article thumbnail

STAT+: Health care lobbying giants spent big as little got done in Congress

STAT

WASHINGTON — Congress did nothing this spring to rein in how pharmacy benefit managers operate, which is precisely the outcome the industry’s lobbyists wanted. And the PBM industry spent big to get that result, new disclosures show. The Pharmaceutical Care Management Association, the industry’s biggest trade group, spent a whopping 71% more on lobbying in the first three months of this year compared with 2023, increasing its spending from $2.8 million to $4.8 million.

Packaging 311
article thumbnail

BioMarin Pharmaceutical gets grant for treatment of adolescent PKU patients using AVPAL variant

Pharmaceutical Technology

Discover how BioMarin Pharmaceutical's patent for PAL variants offers a groundbreaking method to treat PKU in adolescents. Administering AvPAL variants weekly over 50 weeks effectively reduces blood phenylalanine levels.

96
article thumbnail

Roche wins FDA OK for targeted drug in early lung cancer

BioPharma Dive

The new label for Alecensa makes it the first targeted treatment available after surgery for people with ALK-positive lung tumors, who are at high risk for brain metastases.

Labelling 110
article thumbnail

Reshoring the UK pharmaceutical supply chain for future resilience

pharmaphorum

Learn about the importance of reshoring the UK pharmaceutical supply chain for future resilience. Discover how this strategic move can enhance local production and secure the availability of critical medications.

115
115
article thumbnail

Biocon signs licensing and supply pact with Biomm S.A for Semaglutide commercialisation in Brazil

Express Pharma

Semaglutide (gOzempic), which is used to improve glycemic control in adults with type-2 diabetes Biocon announced the signing of an exclusive licensing and supply agreement with Biomm S.A., a specialty pharmaceutical company in Brazil, for the commercialisation of its vertically integrated drug product, Semaglutide (gOzempic), which is used to improve glycemic control in adults with type-2 diabetes.

Diabetes 105
article thumbnail

Opinion: Free med school tuition won’t solve the shortage of primary care physicians

STAT

Last month, nearly 40,000 medical students were accepted into residency programs on “Match Day.” Surrounded by family and friends, these soon-to-be-physicians opened envelopes revealing where they would begin their careers. This moment marked the culmination of a residency match process that requires medical students to make a series of choices and rankings about which medical specialty to practice and at which health system, along with the various lifestyle factors inherent in suc

332
332
article thumbnail

Health Canada approves Merck’s KEYTRUDA for gastric cancer treatment

Pharmaceutical Technology

Health Canada has approved Merck’s KEYTRUDA (pembrolizumab), an anti-programmed cell death protein 1 (PD-1) therapy for use in combination with fluoropyrimidine- and platinum-containing-chemotherapy as a first-line treatment for adult gastric cancer patients.

article thumbnail

Lilly to buy injectable drug plant in manufacturing ramp-up

BioPharma Dive

The acquisition of a Nexus Pharmaceuticals facility in Wisconsin could help Lilly better meet demand for injectable medicines, like those it makes for diabetes and obesity.

article thumbnail

AI in Medical Communications: Revolutionising the present, redefining the future

pharmaphorum

Discover how AI is transforming medical communications and reshaping the future of healthcare. Learn about the latest trends, technologies, and advancements in this rapidly evolving field.

article thumbnail

She was fired after not endorsing Splenda-filled salads to people with diabetes. Why? | Neil Barsky

The Guardian - Pharmaceutical Industry

Elizabeth Hanna says she was fired by the American Diabetes Association after refusing to approve recipes heaped with the additive made by a major donor Elizabeth Hanna had a simple job: help people with diabetes figure out what to eat. Anyone with common sense knows this should probably not entail foods that might increase people’s risk of getting diabetes.

Diabetes 110
article thumbnail

STAT+: How a scientific slip-up caused a pregnant woman to get an untested treatment for preterm birth

STAT

Makena, once the only available treatment to prevent preterm birth, has had its share of controversy. A yearslong debate over the drug’s effectiveness led the Food and Drug Administration to withdraw its approval of the product and demand it be pulled from the market after a confirmatory trial couldn’t replicate the results of a key study.

325
325
article thumbnail

GS-6212 by Gilead Sciences for Human Immunodeficiency Virus (HIV) Infections (AIDS): Likelihood of Approval

Pharmaceutical Technology

GS-6212 is under clinical development by Gilead Sciences and currently in Phase I for Human Immunodeficiency Virus (HIV) Infections (AIDS).

98
article thumbnail

Bristol Myers taps startup to boost CAR-T production

BioPharma Dive

A partnership with Cellares, worth up to $380 million, is meant to help Bristol Myers speed and scale manufacture of the complex cellular treatments.

101
101
article thumbnail

FDA clears ImmunityBio’s bladder cancer drug at 2nd attempt

pharmaphorum

After rejecting ImmunityBio’s Anktiva last year, the FDA has now cleared the drug as a treatment for bladder cancer, making it the biotech's first commercial-stage product

98
article thumbnail

On the Go: Pharmacy Solutions for Summer Travel Medications

PioneerRx

The summer is rapidly approaching. From getting ready for graduation ceremonies to preparing for your favorite user conference (hello, Catalyst Connect 2024).

90
article thumbnail

Biden administration finalizes abortion privacy protections

STAT

WASHINGTON — Biden officials are still pressing to shore up abortion protections amid an onslaught of legal challenges, one of which is slated for Supreme Court arguments this week. The Department of Health and Human Services on Monday released a final rule that would put abortion services under the same federal privacy protections as other health care data covered by the Health Insurance Portability and Accountability Act, or HIPAA.

HIPAA 319